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Squamous cell carcinoma of the head and neck (head and neck cancer) accounts for over 95% of all 
cancers of the oral cavity, oropharynx, larynx and hypopharynx [1] and it is the 6
th
 most common 
cancer disease worldwide. It is the cause of 550 000 cancer deaths annually, the majority of these in 
the lesser developed world. [2] Treatment options are surgery, radiotherapy and chemotherapy. [1] 
There has been little improvement on survival the last decades, and loss of locoregional control and 
secondary tumors despite treatment are frequent. [1] Head and neck cancer also have been shown 
to have developed mechanisms to evade the immune system. [3] There is a great interest in finding 
new and more personalized treatment options for these patients, with targeted therapy and with 
immune therapy, to improve survival but also to decrease treatment related morbidity. [1], [3]. 
Cationic antimicrobial peptides (CAP`s) are a naturally occurring part of the innate immune system 
[4], and some have shown anticancer activity. [4] De nouvo designed shorter CAP`s have proved to 
kill cancer cells by cell lysis in vitro and by tumor lysis and concurrent immunization of the tumor in 
vivo. [5] In this study we show that two de nuovo designed antitumor peptides show efficacy against 
a panel of HN cancer cells in vitro, these findings indicate that treatment with lytic peptide has a 







Head and neck cancer 
The development of head and neck cancer is linked to alcohol consumption and cigarette smoking, 
and also more recently with human papilloma virus (HPV) infection. [6] HPV infected patients benefit 
from a paradoxally better prognosis compared to HPV negative patients. It has been suggested that 
this might be due to younger age and better overall health status than patients who develop head 
and neck cancer without HPV infection. [6] With the exception of HPV positive patients, very little 
progress has been reported on the disease outcome in HN cancer patients in the last 30 years. [6] 
Today’s treatment options includes surgery, radiotherapy and conventional chemotherapy and for 
some patients also EGFR receptor antibodies. The prognosis for these patients is rather poor, with a 5 
year survival of approximately 40-50%. [1] But despite the fact that little progression has been made 
to increase patient survival, it is assumed that the last decades development in surgery and organ 
preserving treatment regimen has had a positive impact on the patient’s life quality. [1]  
Background, cationic antimicrobial peptides (CAP`s) 
Antimicrobial peptides are a naturally occurring part of the innate immune systems defense against 
prokaryote cells, fungi, protozoa and viruses, and can be found throughout the animal kingdom. [7] A 
large number of these natural peptides have been isolated and have been models for synthetic 
variants, and a number of these peptides have been reported to exhibit anticancer activity. [4] 
Antimicrobial peptides are a heterogeneous group of molecules, in regards to both primary and 
secondary structure, the majorities are short peptide(5-25aa), cationic and amphipatic. The negative 
charged prokaryote membrane attracts the positively charged peptides, and the amphipatic nature 
of the peptides enables it to interact with and disrupt lipid membranes. [4] Bovine lactoferricin is one 
such natural occurring CAP, from bovine milk. This peptide has been reported to exhibit antimicrobial 
properties, but also to kill cancer cells both in vitro by necrosis and apoptosis and to inhibit tumor 
growth in vivo with intratumoral injections [8-10].  With extensive structure activity studies and 
optimization of the different structural parameters critical for the anticancer activity, [11-13] a family 
of 9-mer peptides were developed using LactoferricinB as a model peptide. These shorter peptides 
have a α −helical secondary structure and contains one bulky unnatural (non coded) amino acid. 
They effectively kill cancer cells in vitro, even cell lines known to be resistant to conventional 
cytostatic drugs. In vivo they cause tumor regression after intratumoral injections, and in immune 
competent mice causes long term protection even when reinocculated, apparently immunizing the 






LM1  peptide was synthesized in the peptide laboratory at UiT by the author, using solid phase 
method using Fmoc chemistry on a Pioneer Peptide synthesizer (Applied Biosystem, Foster City, CA) 
and purified using high-pressure liquid chromatography (HPLC, Waters Corporation, Milford, MA, 
USA). The integrity of the peptide was confirmed my mass spectrometry (VG instruments Inc.) LM2 
peptide was made to order by Bachem. 
Both peptides were 9-mers, containing one unnaturally occurring, bulky amino residue. The main 
difference between these two peptides is the placement of this residue. 
Cell lines 
Primary squamous cell carcinomas cells from human head and neck cancer patients were obtained 
from cancer patients as previously described [14]. Cells were cultured in high glucose DMEM medium 
containing 1% L-glutamine, 10% fetal bovine serum. Cell lines were purchased from ATCC, (Manassas, 
VA). FEMX, HT-29, MDA-MB-435 were  cultured in RMPI containing 1% L-glutamine and 10% fetal 
bovine serum,  DU-145, ATCC-SCC 9 and 25 were cultured in high glucose DMEM containing  1% L-
glutamine and 10% fetal serum albumin. All cell cultures were maintained in absence of antibiotics in 
a humidified atmosphere at 37C and 5%CO2.  
Viability assay, MTT 
This assay is used to determine the amount of viable cells after treatment with cytotoxic reagents, 
and the method is widely used in drug development studies . It is a fast, reliable and cost effective 
way to determine toxic effect of drugs and cell viabibility.  MTT is added to cells after the desired 
treatment, and will penetrate into cells and in the mitochondria be reduced to a formazan product 
that can be dissolved in the media after alcohol lysis of the cells. The absorbance can be measured by 
a plate reader at 590nm, and the amount of formazan in each well is directly proportional with the 
amount of living cells. The percentage of living cells is calculated by using the following equation: 
(A=absorbance) 
(A treated cells – A positive control)/ (A negative control – A positive control) X 100 
Cells were cultured until a confluence of 80%, trypsinated and a sample of the cells were counted. 
Cells were transferred to a falcon tube, centrifuged at 3000rpm for 5 minutes before they were 
diluted in growth medium and seeded into 96 wells plate.  Number of cells depending on cell line, 
10 000, 15 00 or 20 000 cells per well in 100 uL growth medium. Cells were then allowed to attach for 
16 hrs. Cells were washed with serum free RPMI (assay medium) twice before treated with peptide. 
Peptide was weighed at 1mg, then dissolved in assay medium to a concentration of 2000ug/ml, and 
thereafter diluted in 8 concentrations from 10-500ug/ml, and added to the cells with 3 parallels for 
each concentration. Positive control was 1% Triton-X and negative control was assay medium only.  
Cells were incubated with peptide for 4 hours before 10 uL MTT was added to each well followed by 
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2 hours incubation. Then 70 uL media was carefully removed from each well before 100uL acid 
isopropanol was added. The plate was gently mixed before absorbance was measured. Final results 
were calculated using the mean of three experiments, each with triplicate wells. For a few of the 
cells, the experiment was only conducted twice due to extreme slow growth. (UT-SCC 16, 33 & 48)  
Results 
Both peptides are effective against HN cancer cell in vitro 
The efficacy of the short lytic lytic peptides against HN cancer cells was determined with MTT-assay 
and IC-50 value was compared to the IC-50 value of 4 human cancer cell lines known to be sensitive 
to peptide treatment. (Table 1 & 2, figure 1 & 2)  Median IC-50 value for LM1 peptide was 58,5 uM in 
the HN cancer cells and 56,5 uM in the other cancer cell lines tested. For LM2 peptide the median 
value was 26,5 uM in the HN cancer cells and for the other cancer cells the median value was 25 uM. 
Table 1 and 2 and figure 1 & 2. It should also be noted that this effect was measured after a short 
incubation time, of only 4 hours. 
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Table 1       Table 2     
  
LM-1 peptide   LM-2 peptide  
HN SCC cells IC-50 µM  HN SCC cells IC-50 µM 
UT-SCC-16A  31  UT-SCC-16A * 15 
UT-SCC-59C 38  UT-SCC-59C 17 
ATCC-SCC-9  43  UT-SCC-34A 17 
UT-SCC-34A 43  UT-SCC-24A 17 
UT-SCC-24A 48  ATCC-SCC-9  22 
UT-SCC-1A 52  ATCC-SCC-25 26 
UT-SCC-48 * 65  UT-SCC-1A 27 
ATCC-SCC-25 69  UT-SCC-63A 29 
UT-SCC-33   76  UT-SCC-33 * 30 
UT-SCC-63A 82  UT-SCC-48 * 32 
UT-SCC-54B 100  UT-SCC-54B 34 
UT-SCC-9 109  UT-SCC-9 38 
         
Other cancer cells IC-50 µM  Other cancer cells IC-50 µM 
MDA-MB-435 Melanoma 39  MDA-MB-435 Melanoma 17 
FEMX  Melanoma  53  FEMX  Melanoma 24 
HT-29 Colon carcinoma 60  DU-145 Prostata  26 
DU-145 Prostata  69  HT-29 Colon carcinoma 34 
      
Normal cells IC-50 µM  Normal cells IC-50 µM 
MRC-5 human fibroblast 129  MRC-5  human fibroblast  26 
   HUVEC human endothel 23 
 







Figure 1 & Figure 2: IC-50 values of the tested LM-1 and LM-2 peptides. Blue colored colonna’s 
represent HN cancer cells, red colored represent other cancer cell lines and green represent 




Differences in peptide sensitivity between cells 
The HN cancer cells tested showed diversity in sensitivity for both the peptides tested. (Table 1 & 2, 
figure 1 & 2)   The differences were most pronounced for the LM-1 peptide was the sensitivity ranged 
from 31uM in the most sensitive culture, to 109uM in the most resistant culture. For the LM-2 
peptide HN cancer cells demonstrated IC-50 values ranging from 15 to 38uM. It was much the same 
pattern of sensitivity for both peptides. There were also a varying sensitivity for the peptides 
amongst the other cancer cell lines tested, but none showed as high IC-50 values as the most 
resistant HN cancer cells. Also for the other cancer cells, largely the same pattern of sensitivity could 
be recognized between the two different peptides tested.  
Differences in activity between LM-1 and LM-2 peptide 
For the HN cancer cells, the LM-1 peptide had a mean IC-50 value of 63uM while LM-2 had a mean 
IC-50 value of 25,3uM. For the other cancer cells the mean IC-50 value for the LM-1 peptide was 
55,3uM and for LM-2 peptide the mean IC-50 value was 25,3 uM. The LM-2 peptide showed greater 
activity compared to the LM-1 peptide, and also a more homogenous activity between the different 
cultures. (Table 1 & 2, figure 1 & 2)   
Discussion 
The peptides tested showed diverse between the cell lines, and also between the different peptides. 
Both peptides showed activity against the human HN cancer cells, as compared to the activity against 
the four cancer cell lines that were tested. These data indicates that lytic peptides may be a novel 
therapeutic approach against HN cancer in human patients. Also it can be assumed that the 
characteristics that is suggested to make cancer cells more sensible for peptide treatment, namely 
increased membrane fluidity [15], increased membrane surface due to a high amount of microvili 
[16] and the relative amount of different charged membrane components like phosphatidylserine 
[17], are also present in the squamous cell carcinoma cells of the head and neck cancers, as in many 
other cancer cells.  
The two tested peptides also shows a difference in specificity against cancer cells compared to 
normal cells. While the LM1 peptide showed a greater activity against cancer cells as compared to 
normal human fibroblasts, the LM-2 peptide were also active against normal human fibroblasts and 
endothelial cells. When considering the suggested intratumoral administration of the peptide 
treatment in human patients, this lack of specificity toward tumor cells might not be a disadvantage. 
It is known that cells in the tumor microenvironment are contributing to the tumor progress and that 
this tumor-host interaction is crucial for the tumors growth, ability to metastasize and might even 
contribute to drug resistance [18]. Thus targeting the whole tumor mass included associated vessels 
and fibroblasts might be more effective than lysis of the tumor cells alone. Considering the patient 
safety, the LM-2 peptide has previously shown no hemolytic activity, and also the half-life in plasma 
is approximately 15 minutes (data not shown).    
The variety of the sensitivity between different cells is notable, especially in regard to the LM-1 
peptide. The most resistant cell culture had an IC-50 value more than a threefold over the most 
sensitive cell culture. This might be caused by different membrane composition in the more resistant 
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cells; a less negatively charged membrane surface would be less likely to attract the cationic peptides 
to its surface. A higher amount of cholesterol would likely help stabilize the membrane and inhibit 
membrane collapse at a lower concentration, thus elevating the IC-50 value. These are two examples 
of how a different membrane composition might inhibit the peptides killing effect on some cell types. 
It has also been proved that the LM2 peptide in lower concentrations enters the cells cytoplasm and 
causes destabilization of the mitochondrial membrane (data not shown, authors 
“Forskerlinjeoppgave”), and it is likely that the effect of this mitochondrial attack contributes to the 
cytotoxicity in lower concentrations. It is shown that cancer cells might also harbor changes in the 
mitochondria like hyperpolarization [19]  and it is not unlikely that this mitochondrial transformation 
might render the cell more susceptible for peptide attack. The number of mitochondria also varies 
greatly amongst different cell types, and this might also influence the sensitivity of a certain cell line 
to the peptide treatment. It is also known that HN cancers also harbors a great heterogeneity 
anatomically, even to such a degree that it might be discussed whether they might be considered 
one disease entity.  [20] Different anatomical sites means different microstructure, different 
microenvironment, including blood supply, venous and lymphatic drainage. All this would quite 
possibly lead to different phenotypes, and could influence on the sensitivity of the cell lines to 
peptide treatment.  
Conclusion 
This panel study demonstrates that the short lytic anticancer peptides LM1 and LM2 are effective 
against human head and neck cancer cell lines, with the LM2 peptide being the most active. The 
tested cell lines also shows a variety in sensitivity, this result is as expected considering the multiple 
anatomical locations the tested cell lines were derived from.  
Further studies in vitro should include testing against cells from so called pre-malignant lesions 
(leukoplakia and eryplakia) which may prelude malignant transformation in the squamous epithelia 
of the oral cavity. Also further studies should aim at testing the peptide on HN cancer cells in 
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